Pancreatic Cancer Clinical Trial
Official title:
The Italian Version of the Cancer Worry Scale . A Pancreatic Context Adaptation and Reliability Analysis
An Italian language version of the Cancer Worry Scale is not available yet.
The aim of this study is to develop and validate the Italian version of Cancer Worry Scale
through subjects at high risk of pancreatic cancer for familiarity/genetic predisposition, or
suffering from premalignant cystic lesions.
The Fear of Cancer remains a significant problem for subjects enrolled surveillance programs.
This emotional condition can influence the patients' wellbeing and their adherence to
treatments. No results coming from the application of Cancer Worry Scale on high-risk of
Pancreatic cancer individuals have been provided yet.
The fear is an emotional reaction that can be the result of interpretation and cognitions of
perceived internal cues and/or external cues. To objectify this emotion, a cancer worry
scale, has been developed to investigate the fear in female breast cancer survivors. The
proposed scale assesses the psychological distress caused by fear of cancer.
The detection of high level of fear can prevent problematic behaviours, including anxious
preoccupation, avoidance, and excessive checking, and moreover it can help patients to reduce
difficulties in performing the individual's daily and social activities. The scale could use
to evaluate the psychological burden produced by the enrolment in a surveillance program due
to a certain predisposition to Pancreatic cancer. One step forward will be to manage those
individuals with high-level of Fear of cancer, providing them a proper psychological support.
At the General and Pancreatic Surgery Unit of the Pancreas Institute, some experimental
self-made psychological support programs that investigate different psychologic distress
through validated instruments, like anxiety, depression, perceived stress and global
assessment or quality of life have been built up. It must be noted that the scale is not
available specifically for Pancreatic cancer (originally it was created for breast cancer) ,
and for the Italian language, thus it has never been applied in an italian
surveillance/follow-up program dealing with Pancreatic cancer. Nowadays, there is only a
well-structured paper assessing psychological factors associated with cancer worries in high
risk participants in a pancreatic cancer surveillance program. Differently than what has been
already reported by Konings et al, the cohorts of patients that will be considered are
heterogeneous, reflecting more accurately the real-life scenario of the subjects to whom the
scale is administered to. In addition, this may help to identify those individuals that may
benefit from a psychological support, in order to prevent a withdrawal from the surveillance
program.
However, a cut-off has not been provided yet. With next step study we'll aim at determining a
cut-off for the detection clinically relevant worry for cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|